The following statement is being issued by Jonathan Schochor, Chairman, Plaintiffs’ Steering Committee, regarding Jane Doe No. 1, et. al. v. Johns Hopkins Hospital, et al., No. 24-C-13-001041.
If you were a patient of, or treated by Johns Hopkins Hospital gynecologist, Dr. Nikita Levy, you are a member of a mandatory settlement class action.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65136-dr-nikita-levy-class-action-lawsuit-johns-hopkins-hospital-gynecology
The following statement is being issued by Jonathan Schochor, Chairman, Plaintiffs’ Steering Committee, regarding Jane Doe No. 1, et. al. v. Johns Hopkins Hospital, et al., No. 24-C-13-001041.
If you were a patient of, or were treated by Johns Hopkins Hospital gynecologist, Dr. Nikita Levy, you may be eligible for compensation from a class action Settlement
A $190 million dollar proposed Settlement has been reached that offers payments to eligible members of The Levy Settlement Class.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7281851-dr-nikita-levy-patients-class-action-settlement/
The Kiran Infertility Centre- KIC is a Super Specialty Facility dealing in Infertility Treatments & Surrogacy. An ISO 9001- 2008 Company, KIC with its cutting-edge technology, world-renowned experts and a patient-centric approach, has been a dominant player in the area of Fertility Treatments and is one of the oldest facilities in India offering Infertility Treatment. Dr Sekhar Samit
The Kiran Infertility Centre- KIC is a Super Specialty Facility dealing in Infertility Treatments & Surrogacy. An ISO 9001- 2008 Company, KIC with its cutting-edge technology, world-renowned experts and a patient-centric approach, has been a dominant player in the area of Fertility Treatments and is one of the oldest facilities in India offering Infertility Treatment. Dr Samit Sekhar
The Kiran Infertility Centre- KIC is a Super Specialty Facility dealing in Infertility Treatments & Surrogacy. An ISO 9001- 2008 Company, KIC with its cutting-edge technology, world-renowned experts and a patient-centric approach, has been a dominant player in the area of Fertility Treatments and is one of the oldest facilities in India offering Infertility Treatment. Dr Pratima Grover
Joerns Healthcare has launched the Dolphin Fluid Immersion Simulation® system that more effectively prevents and treats pressure-related injuries than other surfaces. This patented technology simulates the effect of floating in water for patients on hospital beds, stretchers, and in wheel chairs. The Dolphin technology continually adjusts to the patient’s body, promoting tissue perfusion and oxygenation, and minimizing injury related to compromised blood flow. The Dolphin is also proven to accelerate healing of advanced stage or multiple pressure ulcers, muscle flaps, skin grafts, burns and other wound conditions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58463-joerns-dolphin-fluid-immersion-simulation-system-pressure-related-injuries
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans. Furthermore, only 33% said they were encouraged by their healthcare professional to ask questions in the consultation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment
Close-Up TV News recognizes Diamond Dental Care for its commitment to quality patient care.
Servicing its community for over 30 years, Diamond Dental Care is a family owned and operated dental practice specializing in the full spectrum of lifelong dental care. Lead by Dr. Fred Turner, Diamond Dental Care’s goal is for each patient to leave with their best smile possible through durable, functional and clinically sound treatments that also provide aesthetically pleasing and natural results.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/diamonddental/45801/
Today’s U.S. healthcare providers face a three-pronged deluge of demands from patients, insurance companies, and the government. To successfully address these new and evolving expectations, members of the medical sector must leverage the capabilities of new wireless technologies – or fall behind their more savvy competitors.
Frost & Sullivan recently published a whitepaper, Mobile Devices and Healthcare: What’s New, What Fits, and How Do You Decide?, which examines the strengths and drawbacks of four major mobile device types – smartphones, tablets, push-to-talk communication devices, and machine-to-machine (M2M) remote medical monitoring devices. Each device category is evaluated for application in three unique environments – the hospital, physician’s office, and the patient’s home. Criteria for selecting a mobility partner are also discussed.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/51532/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
"Skin care depends on detail. #Dermatologytranscription services at MTS transform dictations into structured, #HIPAA-secure reports that keep treatment plans intact.
Fast, precise, and specialty-aware — so every observation is documented clearly, and every patient receives care without delay."
Cutanea Life Sciences, Inc. (CLS), an emerging U.S. prescription product development company, formally unveiled its new digital presence, www.cutanea.com, to the dermatology community in conjunction with this winter’s annual gathering of dermatologists from the U.S and around the world. CLS has a stream of innovative product candidates in different stages of development that cover an array of skin conditions, including acne, rosacea, psoriasis and warts caused by human papillomavirus (HPV).
CLS’s new digital presence demonstrates the company’s intent to change the way that customers think about a valued dermatology partner. CLS believes that it can make an impact in the current state of dermatology practice through its commitment to focus on unmet and underserved patient needs. In turn this will help medical professionals optimize their practice time through CLS products and services.
To view the multimedia release go to:
http://www.multivu.com/players/English/7743651-cutanea-life-sciences-dermatology/
